FDA 483 - Jiangsu Anbison Pharmaceutical Co., Ltd. - July 16, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Jiangsu Anbison Pharmaceutical Co., Ltd. in Taizhou, China, revealed significant deficiencies in their manufacturing operations. Observations included inadequate quality control unit procedures for reviewing audit trails, insufficient validation of aseptic processes for sterile drug products, and deficiencies in environmental monitoring within aseptic processing areas. These issues indicate a lack of control over critical manufacturing processes and data integrity.
ID · 1f15e594-e0fe-4ce3-89a0-012e7b14b791